Wellgistics enters LOI to evaluate potential acquisition of Neuritek

Wellgistics Health (WGRX) announced that it has entered into a non-exclusive, non-binding Letter of Intent, LOI, to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed all stock transaction, if completed, is intended to enhance Wellgistics existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.